Compare Novavax Inc (NVAX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Prospect Capital Corporation — how do they compare? Novavax Inc trades at $7.95 (market cap $1.30B), while Prospect Capital Corporation trades at $2.27 (market cap $1.15B). The key difference: Novavax Inc and Prospect Capital Corporation are close in size by market cap, and Prospect Capital Corporation pays a 21.83% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PSEC | |
|---|---|---|
Market Cap | $1.30B | $1.15B |
Sector | Health | Financials |
52-Week High | $11.19 | $3.05 |
52-Week Low | $6.22 | $2.11 |
Enterprise Value | $879.40M | — |
Dividend Yield | — | 21.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
PSEC trades at $2.33, up 5.43% in the last session, with a neutral technical signal and bearish moving averages. The company shows mixed fundamentals, with a low P/B of 0.4 and recent quarterly EPS beats, but negative revenue and net income in 2025. Recent news highlights a dividend increase for an affiliate fund and the sale of Valley Electric for a 4.8x return.
Outlook is cautious; the stock offers value with a low P/B and dividend yield, but significant risks include persistent negative profitability, high P/S ratio, and analyst skepticism. Investment appeal hinges on portfolio turnaround and sustained dividend stability amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
